Lisocabtagene Maraleucel (Breyanzi): A Comprehensive Clinical and Scientific Monograph

Executive Summary

Lisocabtagene maraleucel (liso-cel), marketed as Breyanzi, represents a significant advancement in the field of cellular immunotherapy for B-cell malignancies. It is a second-generation, autologous, CD19-directed chimeric antigen receptor (CAR) T-cell therapy. A defining feature of its molecular design and manufacturing process is the administration of a defined composition of CD4+ and CD8+ CAR-positive T-cells at a consistent 1:1 ratio, a strategy intended to produce more predictable cellular kinetics and a manageable safety profile. The therapy has demonstrated transformative efficacy in patients with relapsed or refractory (R/R) B-cell cancers, leading to durable remissions in populations with historically poor prognoses.

Clinical development has established lisocabtagene maraleucel as a new standard of care in the second-line treatment of large B-cell lymphoma (LBCL), based on the pivotal Phase 3 TRANSFORM trial, which showed a profound improvement in event-free survival over high-dose chemotherapy and autologous stem cell transplantation. Its efficacy is further supported by the TRANSCEND NHL 001 and PILOT studies, which established its value in third-line or later LBCL and in transplant-ineligible patients, respectively. The therapeutic scope has expanded to include R/R follicular lymphoma (FL), mantle cell lymphoma (MCL), and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

Clinically, lisocabtagene maraleucel is distinguished by a favorable safety profile relative to other commercial CAR T-cell therapies. While carrying the class-wide boxed warnings for Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), the incidence of severe (Grade ≥3) events is consistently low. This manageable toxicity has facilitated its successful administration in outpatient settings. However, logistical challenges, including a manufacturing time that can extend to several weeks, remain a critical consideration in clinical practice. The selection of lisocabtagene maraleucel versus other CD19-directed CAR T-cell products involves a nuanced assessment of efficacy, toxicity, and logistical factors tailored to the individual patient's clinical status and disease tempo.

Molecular Biology, Mechanism of Action, and Cellular Kinetics

The Chimeric Antigen Receptor (CAR) Construct

Lisocabtagene maraleucel is a genetically modified autologous T-cell immunotherapy that harnesses the patient's own immune system to target and eliminate malignant B-cells.[1] The core of this technology is the chimeric antigen receptor, a synthetic protein engineered to be expressed on the surface of the patient's T-cells.

The CAR construct of lisocabtagene maraleucel is composed of several key functional domains [2]:

1. Extracellular Targeting Domain: This consists of a murine FMC63 monoclonal antibody-derived single-chain variable fragment (scFv). This domain is responsible for recognizing and binding with high specificity to the CD19 antigen, a protein broadly expressed on the surface of normal and malignant B-lineage cells.[1]
2. Hinge and Transmembrane Domain: An immunoglobulin G4 (IgG4) hinge region provides flexibility to the scFv, while a CD28 transmembrane domain anchors the entire CAR protein within the T-cell's plasma membrane.[3]
3. Intracellular Signaling Domains: Upon binding of the scFv to CD19, intracellular signals are transmitted that activate the T-cell. Lisocabtagene maraleucel is a second-generation CAR, containing two distinct signaling domains:

• 4-1BB (CD137) Costimulatory Domain: This domain is crucial for enhancing the expansion, metabolic fitness, and long-term persistence of the CAR T-cells following activation.[1]
• CD3$\zeta$ Activation Domain: This is the primary T-cell receptor signaling component that initiates the cytotoxic effector functions of the T-cell, leading to the killing of the target B-cell.[1]

Additionally, the lentiviral vector used to transduce the T-cells co-expresses a non-functional, truncated version of the human epidermal growth factor receptor (EGFRt). This protein is expressed on the surface of the CAR T-cells and serves two purposes: it acts as a surrogate marker for in vivo tracking of the modified cells, and it provides a potential safety mechanism, as the EGFRt-positive cells can be targeted for elimination by the monoclonal antibody cetuximab through an antibody-dependent cellular cytotoxicity (ADCC) response.[1]

The Defined Composition: A Key Differentiator

A unique and central feature of lisocabtagene maraleucel is its defined cellular composition. Unlike first-generation commercial CAR T-cell therapies that are manufactured from a bulk population of peripheral blood mononuclear cells, the manufacturing process for lisocabtagene maraleucel involves the separate purification, activation, and lentiviral transduction of the patient's CD4+ (helper) and CD8+ (cytotoxic) T-cell subsets.[1] The final product is formulated to contain a precise 1:1 ratio of CD4+ and CD8+ CAR-positive T-cells, which are then administered to the patient as two sequential infusions.[1]

This design is predicated on a strong immunological rationale. CD8+ T-cells are the primary effectors responsible for directly killing tumor cells. CD4+ T-cells, often termed "helper" cells, play a critical role in orchestrating a robust and durable immune response by providing cytokine support that promotes the proliferation, survival, and memory formation of CD8+ effector cells. By controlling the input ratio of these two critical T-cell subsets, the therapy is designed to generate a more consistent and balanced in vivo cellular expansion and persistence across patients.[7] This contrasts with products derived from bulk T-cells, where the final CD4/CD8 ratio is variable and dependent on the patient's starting apheresis material.[5] This molecular-level decision to enforce a defined composition is a foundational element of the therapy's design, likely contributing to its distinct clinical profile, particularly its manageable safety characteristics, by avoiding the uncontrolled and explosive T-cell proliferation that can lead to severe toxicities.

Cellular Kinetics (Pharmacokinetics) and Pharmacodynamics

Following a single intravenous infusion, the cellular kinetics of lisocabtagene maraleucel are characterized by a multiphasic pattern. A population cellular kinetic model based on data from the TRANSCEND NHL 001 trial described this behavior using a piecewise model that includes [3]:

• A lag phase with a mean duration of approximately 3.3 days.
• An exponential growth phase with a mean doubling time of approximately 0.76 days.
• A biexponential decay phase, consisting of an initial decline followed by a long terminal phase.

The CAR T-cells reach maximum concentration (Cmax​) in the peripheral blood at a median of 9 to 12 days post-infusion.[3] The persistence of these cells is notable; the terminal half-life is estimated to be approximately 352 days, and CAR T-cell transgenes have been detected in patients' blood for up to two to three years after infusion, indicating the establishment of a long-lasting cellular reservoir.[3]

The pharmacodynamic relationship is clear: higher levels of CAR T-cell expansion, as measured by Cmax​ and the area under the curve (AUC), are associated with higher objective response rates.[3] However, this robust expansion is also correlated with a higher incidence of CRS and neurologic toxicities.[3]

Despite the product's design for compositional consistency, significant between-subject variability in the magnitude of CAR T-cell expansion is observed. A comprehensive population kinetic analysis evaluated numerous baseline covariates, including patient age, disease characteristics, and co-administered drugs, but found that none had a clinically meaningful impact on liso-cel kinetics.[3] This suggests that the substantial variability in individual patient outcomes is not easily predicted by standard clinical parameters. The intrinsic biological quality and fitness of the patient's starting T-cells, which are influenced by factors such as prior therapies and the patient's underlying immune status, are likely the dominant drivers of

in vivo kinetic behavior. This reality underscores the necessity for vigilant clinical monitoring of all patients post-infusion, as mandated by the therapy's Risk Evaluation and Mitigation Strategy (REMS), because it is not possible to reliably predict a priori which patients will experience the most robust expansion and, consequently, the highest risk of toxicity.

Clinical Development and Efficacy in Large B-Cell Lymphoma (LBCL)

The clinical development program for lisocabtagene maraleucel has systematically established its efficacy across multiple lines of therapy for LBCL, leading to several key regulatory approvals worldwide.

Table 1: Summary of Global Regulatory Approvals and Key Indications for Lisocabtagene Maraleucel
Regulatory Agency
U.S. Food and Drug Administration (FDA)
European Medicines Agency (EMA)
Health Canada

Foundational Efficacy in Third-Line and Later Therapy: The TRANSCEND NHL 001 Study

The pivotal TRANSCEND NHL 001 study, a multicenter Phase 1 trial, established the foundational efficacy of lisocabtagene maraleucel in a heavily pretreated population of adults with R/R LBCL.[7] These patients had a median of three prior lines of therapy and faced a dismal prognosis with conventional treatments, where median overall survival was approximately six months.[7]

In the primary efficacy analysis of 192 evaluable patients, the overall response rate (ORR) as assessed by an independent review committee was 73%, with a remarkable 54% of patients achieving a complete response (CR). The response was rapid, with a median time to first response of one month.[16]

Longer-term follow-up has confirmed the durability of these responses. With a median follow-up of 19.9 months in an expanded cohort of 257 patients, the ORR and CR rates remained consistent at 73% and 53%, respectively. The median duration of response (DOR) was 23.1 months, the median progression-free survival (PFS) was 6.8 months, and the median overall survival (OS) was 27.3 months. The estimated 2-year OS rate was 50.5%, a substantial improvement over historical outcomes.[7]

The most recent 5-year follow-up data have provided evidence of a potential curative plateau. The median OS was 27.5 months, and the estimated 5-year OS rate was 38.1%. Critically, for the cohort of patients who achieved a CR, the median OS was not reached, and the 5-year OS rate was 55.9%.[23] The flattening of the survival curve at this late time point suggests that a significant fraction of responders achieve long-term, durable disease control, fundamentally altering the therapeutic goal for this refractory population from palliation to potential cure.

Revolutionizing Second-Line Therapy in Transplant-Eligible Patients: The TRANSFORM Study

Building on the success in the third-line setting, the Phase 3 TRANSFORM trial was designed to challenge the long-standing standard of care (SOC) for transplant-eligible patients with primary refractory or early relapsing (within 12 months) LBCL.[18] The trial randomized 184 patients to receive either a single infusion of lisocabtagene maraleucel or SOC, which consisted of salvage chemoimmunotherapy followed by high-dose chemotherapy and autologous HSCT in responding patients.[18]

The study met its primary endpoint with overwhelming statistical significance. At a median follow-up of 33.9 months, the median event-free survival (EFS)—a composite measure of time to progression, death, or initiation of new therapy—was 29.5 months in the lisocabtagene maraleucel arm, compared to just 2.4 months in the SOC arm (Hazard Ratio 0.375, p<0.0001).[24] This result unequivocally established lisocabtagene maraleucel as a superior initial therapeutic strategy. Superiority was also demonstrated for key secondary endpoints, including PFS (median Not Reached vs. 6.2 months; HR 0.422) and CR rate.[18]

The analysis of overall survival was confounded by the trial's crossover design, which ethically permitted 66% of patients in the SOC arm to receive lisocabtagene maraleucel upon disease progression.[24] Consequently, the intent-to-treat analysis did not show a statistically significant difference in median OS (HR 0.757).[24] However, this outcome does not reflect a failure of the drug but rather its profound efficacy as a salvage therapy, which "rescued" many patients in the control arm. A prespecified analysis that adjusted for the therapeutic effect of this crossover did demonstrate a significant survival benefit favoring the lisocabtagene maraleucel arm (HR 0.566).[24] The results of TRANSFORM were practice-changing, effectively rendering the prior SOC obsolete and establishing CD19 CAR T-cell therapy as the new second-line standard for this high-risk patient population.

Extending Curative Intent to Transplant-Ineligible Patients: The PILOT Study

The PILOT study, a Phase 2 trial, addressed another critical unmet need: patients with R/R LBCL after one line of therapy who are not candidates for HSCT due to advanced age or comorbidities.[17] This population has historically had very limited options and poor outcomes.

In 61 treated patients, who had a median age of 74 years, lisocabtagene maraleucel demonstrated robust and durable efficacy. The ORR was 80%, with a CR rate of 54%.[27] With a median follow-up of 18.2 months, the median DOR was 23.3 months, and the median OS was not reached, with an estimated 18-month OS rate of 59%.[27] A comparative analysis against real-world data of patients treated with conventional chemotherapy confirmed the statistical superiority of lisocabtagene maraleucel across all efficacy endpoints.[30] Furthermore, the study demonstrated that despite a transient decline immediately following infusion, patients experienced sustained and clinically meaningful improvements in health-related quality of life, particularly in domains of fatigue and pain.[29]

Table 2: Pivotal Efficacy Outcomes of Lisocabtagene Maraleucel in Large B-Cell Lymphoma
Efficacy Endpoint
Patient Population
N (Treated Patients)
Overall Response Rate (ORR)
Complete Response (CR) Rate
Median Duration of Response (DOR)
Median Progression-Free Survival (PFS)
Median Overall Survival (OS)
Landmark OS Rate

Efficacy in Other B-Cell Malignancies

The successful application of lisocabtagene maraleucel in LBCL has prompted its investigation and subsequent approval for other CD19-expressing B-cell cancers.

Relapsed/Refractory Follicular Lymphoma (FL)

In May 2024, the FDA granted accelerated approval to lisocabtagene maraleucel for the treatment of adult patients with R/R FL who have received two or more prior lines of systemic therapy.[14] This approval was based on the single-arm, Phase 2 TRANSCEND-FL trial. In the primary efficacy cohort of 94 patients, the therapy demonstrated exceptional activity, with an ORR of 95.7% and a CR rate of 73.4%. The responses were durable, with a median DOR not reached at a median follow-up of 16.8 months and an estimated 1-year remission rate of 81%.[35]

Relapsed/Refractory Mantle Cell Lymphoma (MCL)

Also in May 2024, the FDA approved lisocabtagene maraleucel for adult patients with R/R MCL who have received at least two prior lines of therapy, including a Bruton's tyrosine kinase (BTK) inhibitor.[4] This indication was supported by data from the TRANSCEND-MCL cohort of the TRANSCEND-NHL-001 study. Among 68 evaluable patients in this difficult-to-treat population, the ORR was 85.3%, and the CR rate was 67.6%. The median DOR was 13.3 months.[19]

Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)

Lisocabtagene maraleucel is also approved under an accelerated pathway for adult patients with R/R CLL or SLL who have progressed after at least two prior lines of therapy, including both a BTK inhibitor and a B-cell lymphoma 2 (BCL-2) inhibitor.[14] This addresses a patient population with very few effective treatment options. Post-marketing studies, such as the recruiting trial NCT06788639, are underway to confirm the clinical benefit and further evaluate its role in this setting.[37]

Comprehensive Safety and Toxicity Profile

The clinical use of CAR T-cell therapies is associated with unique and potentially life-threatening toxicities. The safety profile of lisocabtagene maraleucel is a key aspect of its clinical identity, generally characterized by a lower incidence of severe toxicities compared to some other CAR T-cell products.

Boxed Warnings: Cytokine Release Syndrome (CRS) and Neurologic Toxicities

The U.S. FDA prescribing information for lisocabtagene maraleucel includes a boxed warning for CRS and neurologic toxicities, which are class-wide effects of CAR T-cell therapies.[14]

• Cytokine Release Syndrome (CRS): This is a systemic inflammatory response caused by the activation and proliferation of CAR T-cells and the subsequent release of inflammatory cytokines. Patients can experience symptoms ranging from mild fever and flu-like symptoms to life-threatening hypotension, hypoxia, and organ dysfunction.[14] While any-grade CRS is common, occurring in 45% to 59% of patients treated with lisocabtagene maraleucel, the incidence of severe (Grade ≥3) CRS is consistently low, reported at 1% to 4% across pivotal trials.[16] The median time to onset is approximately 5 days after infusion.[8]
• Neurologic Toxicities (ICANS): Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) can manifest as aphasia, confusion, delirium, encephalopathy, tremor, and seizures.[36] The incidence of any-grade neurologic events with lisocabtagene maraleucel ranges from 15% to 35%, with severe (Grade ≥3) events occurring in approximately 2% to 12% of patients.[16] The onset of ICANS is typically later than CRS, with a median onset of 8 to 9 days post-infusion.[6]

Management of these toxicities is critical and involves prompt supportive care and the administration of targeted therapies such as the IL-6 receptor antagonist tocilizumab and/or corticosteroids.[10] Due to these risks, lisocabtagene maraleucel is available only through a restricted Risk Evaluation and Mitigation Strategy (REMS) program, which ensures that healthcare facilities are certified and trained to monitor for and manage these specific toxicities.[1]

Other Significant Adverse Reactions

Beyond the boxed warnings, other important adverse reactions include:

• Prolonged Cytopenias: Grade ≥3 neutropenia, anemia, and thrombocytopenia are the most frequently reported severe adverse events in the 90-day period following infusion.[7]
• Infections: Patients are at high risk for serious infections due to lymphodepletion, B-cell aplasia, and potential immunosuppressive management of CRS/ICANS. Grade ≥3 infections occurred in approximately 19% of patients in the TRANSCEND trial.[14]
• Hypogammaglobulinemia: The on-target depletion of normal B-cells leads to low immunoglobulin levels, which can be prolonged and may require intravenous immunoglobulin (IVIG) replacement therapy to prevent infections.[1]
• Secondary Malignancies: There is a recognized risk of developing secondary cancers after treatment. In April 2024, the FDA expanded the boxed warning for the entire class of approved CD19- and BCMA-directed autologous CAR T-cell therapies to include the risk of T-cell malignancies.[1]

Safety in Special Contexts: Real-World and Outpatient Settings

An important aspect of the lisocabtagene maraleucel clinical profile is its performance outside of strictly controlled clinical trials. Real-world evidence has confirmed that the manageable safety profile observed in pivotal studies is reproducible in routine clinical practice, including in older patients and those with significant comorbidities who would not have met the eligibility criteria for the original trials.[41]

The favorable safety profile, particularly the low rates of severe CRS and ICANS and a later median time to onset for these toxicities, has supported the administration and monitoring of lisocabtagene maraleucel in the outpatient setting for appropriate patients. Studies have demonstrated the feasibility and safety of this approach, which can reduce the burden of hospitalization and lower healthcare costs.[44]

Table 3: Consolidated Safety Profile: Incidence of Key Grade ≥3 Adverse Events Across Pivotal LBCL Trials
Grade ≥3 Adverse Event
Cytokine Release Syndrome (CRS)
Neurologic Toxicities (ICANS)
Prolonged Neutropenia
Serious Infections

The Treatment Process: A Logistical and Clinical Walkthrough

The administration of lisocabtagene maraleucel is a complex, multi-step process that requires close coordination between the patient, the clinical care team, and a centralized manufacturing facility. Treatment is only available at certified centers that are enrolled in the BREYANZI REMS program.[9]

Patient Evaluation and Apheresis

The journey begins with a comprehensive consultation at a certified treatment center to determine if the patient is an appropriate candidate for CAR T-cell therapy.[48] If deemed eligible, the patient undergoes a procedure called leukapheresis. This process, which typically takes 2 to 6 hours, involves drawing the patient's blood, separating out the T-cells, and returning the remaining blood components to the patient.[8]

Manufacturing and Bridging Therapy

The collected T-cells are cryopreserved and shipped to a specialized manufacturing site. There, they are purified, activated, and genetically modified using a lentiviral vector to express the anti-CD19 CAR. The CD4+ and CD8+ cells are expanded separately and prepared as the final product.[8] This entire manufacturing process takes approximately 3 to 4 weeks, though the time can vary.[38] This period from cell collection to product infusion is often referred to as the "vein-to-vein" time. During this waiting period, patients may require "bridging therapy" with chemotherapy or other agents to control the lymphoma and prevent clinical deterioration.[24] Patients must be counseled on the risk of manufacturing failure, which has been reported to be around 11% in some settings.[8]

Lymphodepletion and Infusion

Once the physician is notified that the final product is available, the patient is prepared for infusion. This involves a 3-day course of lymphodepleting chemotherapy, typically consisting of fludarabine and cyclophosphamide.[8] This chemotherapy regimen temporarily reduces the number of existing lymphocytes in the patient's body, creating a more favorable environment for the infused CAR T-cells to expand and persist. The lisocabtagene maraleucel infusion is administered 2 to 7 days after the completion of lymphodepletion. It is given as two separate, sequential intravenous infusions—one containing the CD8+ component and the other containing the CD4+ component—with each infusion typically taking less than 15 minutes.[36]

Post-Infusion Monitoring and REMS Program

The period immediately following infusion is critical for monitoring and managing potential toxicities. As required by the REMS program, patients must be monitored daily at the certified healthcare facility for the first week after infusion for signs and symptoms of CRS and ICANS.[8] Furthermore, patients are instructed to remain in close proximity to the treatment center for at least 4 weeks post-infusion to allow for prompt medical intervention if toxicities arise.[8] Patients may be hospitalized for management of side effects and are discharged only when their condition is stable. Long-term follow-up is required to monitor for late effects, including cytopenias, hypogammaglobulinemia, and secondary malignancies.[49]

Therapeutic Landscape and Comparative Analysis

Lisocabtagene maraleucel is one of three CD19-directed CAR T-cell therapies approved for R/R LBCL, alongside axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel). While no head-to-head randomized trials have been conducted, data from pivotal trials, real-world retrospective studies, and matching-adjusted indirect comparisons (MAICs) allow for a comparative analysis of their key attributes.

Molecular and Manufacturing Distinctions

The three products differ in their fundamental design and production:

• Costimulatory Domain: Liso-cel and tisa-cel both utilize the 4-1BB costimulatory domain, which is generally associated with slower, more sustained T-cell signaling, potentially leading to better persistence. In contrast, axi-cel uses the CD28 costimulatory domain, which promotes more rapid and potent T-cell activation and proliferation.[5]
• Cell Composition: As previously noted, liso-cel's defined 1:1 CD4+/CD8+ composition is a key differentiator from axi-cel and tisa-cel, which are manufactured from bulk T-cells and have a variable final composition.[12]
• Manufacturing Time: Real-world data indicate a significant logistical difference, with the median vein-to-vein time for liso-cel being longer (approximately 41 days) than for axi-cel (approximately 30 days).[52]

Comparative Efficacy and Safety

The choice between these therapies often involves balancing efficacy, toxicity, and logistics.

• Liso-cel vs. Axi-cel: Real-world studies show that while unadjusted response rates and survival outcomes can be similar, some propensity-score-adjusted analyses suggest a superior PFS for axi-cel.[52] This may be influenced by selection bias, where patients with more aggressive, rapidly progressing disease are preferentially treated with the faster-to-manufacture axi-cel. The trade-off is a distinct difference in safety profiles. Axi-cel is consistently associated with significantly higher rates of any-grade CRS and ICANS, more frequent severe CRS, longer hospitalizations, and a greater incidence of prolonged neutropenia compared to liso-cel.[52]
• Liso-cel vs. Tisa-cel: Liso-cel has demonstrated superior efficacy in the second-line LBCL setting, where the pivotal trial for tisa-cel (BELINDA) failed to show a benefit over standard of care.[12] In the R/R FL setting, MAICs suggest liso-cel achieves a higher CR rate than tisa-cel, with a comparable safety profile.[55]

This complex interplay of factors creates a clinical decision-making framework that can be described as an "Efficacy-Toxicity-Logistics Trilemma." There is no single superior product for all patients. The selection requires a nuanced clinical judgment that weighs the biological urgency of the patient's disease (favoring a faster product like axi-cel), their physiological fitness to tolerate toxicities (favoring a less toxic product like liso-cel), and the logistical constraints of manufacturing timelines and institutional resources. Liso-cel often represents a balanced, lower-risk option suitable for older or less fit patients and for outpatient administration, provided their disease can be controlled during the longer manufacturing period. Axi-cel may be preferred for younger, fitter patients with rapidly progressing disease who require immediate, potent therapy and can be managed through the expected higher toxicity.

Table 4: Comparative Overview of Commercial CD19 CAR-T Therapies for R/R LBCL
Feature
Costimulatory Domain
Cell Composition
Median Vein-to-Vein Time
2L LBCL Approval (U.S.)
Pivotal 3L+ CR Rate
Pivotal 3L+ Grade ≥3 CRS Rate
Pivotal 3L+ Grade ≥3 ICANS Rate

Future Research Trajectories and Unanswered Questions

Despite its success, the development of lisocabtagene maraleucel is ongoing, with research focused on optimizing its use and expanding its applications.

Combination Therapies

A key area of investigation is the combination of lisocabtagene maraleucel with other therapeutic agents to improve outcomes. Active clinical trials are exploring its use with BTK inhibitors like zanubrutinib for Richter's Syndrome (NCT05873712), immune checkpoint inhibitors such as nivolumab, and other immunomodulatory drugs.[56] The goal of these combinations is to enhance CAR T-cell function, overcome tumor microenvironment-mediated resistance, and improve response rates or durability.

Expansion to New Populations and Earlier Lines

Having been established as a standard of care in second-line LBCL, the logical next step is to investigate its role in the first-line treatment of high-risk patients. Future pivotal trials are likely to explore this setting. Concurrently, ongoing studies are evaluating its efficacy in other B-cell malignancies, such as indolent non-Hodgkin lymphomas and in different patient subgroups.[57] The TRANSCEND-OUTREACH-007 trial (NCT03744676), for example, is specifically designed to assess its safety and efficacy in the outpatient setting.[44]

Overcoming Resistance and Improving Manufacturing

Several critical questions remain. A primary challenge is understanding and overcoming mechanisms of resistance, which can include loss of the CD19 antigen on tumor cells or intrinsic T-cell dysfunction and exhaustion. Identifying predictive biomarkers from the patient's apheresis product that can forecast in vivo expansion, efficacy, and toxicity is a high-priority research goal. Furthermore, innovations in the manufacturing process are urgently needed to reduce the vein-to-vein time, as this logistical delay remains a significant clinical hurdle for patients with aggressive disease. To ensure long-term safety and confirm the durability of responses, dedicated long-term follow-up studies are in place to monitor patients for up to 15 years post-infusion.[23]

Conclusion

Lisocabtagene maraleucel has emerged as a cornerstone of modern cellular immunotherapy for B-cell malignancies. Its unique design, featuring a defined 1:1 composition of CD4+ and CD8+ CAR T-cells, underpins a clinical profile that balances profound, durable efficacy with a manageable and predictable safety profile. The therapy has redefined the standard of care for relapsed/refractory large B-cell lymphoma, demonstrating curative potential in a significant subset of patients across second-line, third-line, transplant-eligible, and transplant-ineligible settings. Its expanding approvals in follicular lymphoma, mantle cell lymphoma, and CLL/SLL further solidify its role as a versatile and potent therapeutic agent.

The primary clinical advantages of lisocabtagene maraleucel are its consistent efficacy and its favorable safety profile, characterized by low rates of severe CRS and ICANS, which enables its use in a broader patient population, including the elderly and those with comorbidities, and facilitates outpatient administration. However, the principal challenge remains the prolonged manufacturing time, which can preclude its use in patients with rapidly progressing disease. The choice of lisocabtagene maraleucel within the therapeutic landscape of CD19-directed CAR T-cell therapies is therefore a sophisticated clinical decision, requiring a careful balancing of disease urgency, patient fitness, and logistical considerations. Future research aimed at shortening manufacturing timelines, identifying predictive biomarkers, and exploring rational combination strategies will be crucial to further optimizing the application of this transformative therapy.

Works cited

1. Lisocabtagene Maraleucel - PubChem, accessed September 8, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Lisocabtagene-Maraleucel
2. Lisocabtagene maraleucel (Liso-Cel) for relapsed/refractory diffuse large B-cell lymphoma - NIHR Innovation Observatory, accessed September 8, 2025, https://www.io.nihr.ac.uk/wp-content/uploads/2022/01/13585-Lisocabtagene-maraleucel-for-DLBCL-V1.0-26FEB18-NON-CONF.pdf
3. Population Cellular Kinetics of Lisocabtagene Maraleucel, an Autologous CD19-Directed Chimeric Antigen Receptor T-Cell Product, in Patients with Relapsed/Refractory Large B-Cell Lymphoma - PubMed Central, accessed September 8, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8613160/
4. Lisocabtagene maraleucel: Uses, Interactions, Mechanism of Action ..., accessed September 8, 2025, https://go.drugbank.com/drugs/DB16582
5. Efficacy and Safety of CAR-T Cell Products Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel for the Treatment of Hematologic Malignancies: A Systematic Review and Meta-Analysis - PMC - PubMed Central, accessed September 8, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8350577/
6. (PDF) Population Cellular Kinetics of Lisocabtagene Maraleucel, an Autologous CD19-Directed Chimeric Antigen Receptor T-Cell Product, in Patients with Relapsed/Refractory Large B-Cell Lymphoma - ResearchGate, accessed September 8, 2025, https://www.researchgate.net/publication/352382100_Population_Cellular_Kinetics_of_Lisocabtagene_Maraleucel_an_Autologous_CD19-Directed_Chimeric_Antigen_Receptor_T-Cell_Product_in_Patients_with_RelapsedRefractory_Large_B-Cell_Lymphoma
7. Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001 | Blood | American Society of Hematology, accessed September 8, 2025, https://ashpublications.org/blood/article/143/5/404/498484/Two-year-follow-up-of-lisocabtagene-maraleucel-in
8. BREYANZI® LBCL Process & Manufacturing | For HCPs, accessed September 8, 2025, https://www.breyanzihcp.com/lbcl/process
9. BREYANZI® Treatment Process in R/R CLL & SLL | For HCPs, accessed September 8, 2025, https://www.breyanzihcp.com/cll-sll/process
10. This medicinal product is subject to additional monitoring. This will allow quick identification of - Breyanzi, INN-lisocabtagene maraleucel, accessed September 8, 2025, https://ec.europa.eu/health/documents/community-register/2022/20220404155180/anx_155180_en.pdf
11. BREYANZI U.S. Prescribing Information - Our Medicines, accessed September 8, 2025, https://packageinserts.bms.com/pi/pi_breyanzi.pdf
12. Comparison of axicabtagene ciloleucel and tisagenlecleucel patient CAR-T cell products by single-cell RNA sequencing - PubMed Central, accessed September 8, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12306477/
13. Breyanzi, INN-lisocabtagene maraleucel - European Medicines ..., accessed September 8, 2025, https://www.ema.europa.eu/en/documents/product-information/breyanzi-epar-product-information_en.pdf
14. Lisocabtagene maraleucel - Wikipedia, accessed September 8, 2025, https://en.wikipedia.org/wiki/Lisocabtagene_maraleucel
15. Breyanzi (lisocabtagene maraleucel) FDA Approval History - Drugs.com, accessed September 8, 2025, https://www.drugs.com/history/breyanzi.html
16. FDA approves lisocabtagene maraleucel for relapsed or refractory large B-cell lymphoma, accessed September 8, 2025, https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lisocabtagene-maraleucel-relapsed-or-refractory-large-b-cell-lymphoma
17. FDA Approval Summary: Lisocabtagene Maraleucel for Second-Line Treatment of Large B-Cell Lymphoma - PubMed, accessed September 8, 2025, https://pubmed.ncbi.nlm.nih.gov/38324398/
18. FDA approves lisocabtagene maraleucel for second-line treatment of large B-cell lymphoma, accessed September 8, 2025, https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lisocabtagene-maraleucel-second-line-treatment-large-b-cell-lymphoma
19. Lisocabtagene Maraleucel Approved for Aggressive Lymphoma | Research | AACR, accessed September 8, 2025, https://www.aacr.org/patients-caregivers/progress-against-cancer/lisocabtagene-maraleucel-approved-for-aggressive-lymphoma/
20. FDA D.I.S.C.O. Burst Edition: Breyanzi (lisocabtagene maraleucel), accessed September 8, 2025, https://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-breyanzi-lisocabtagene-maraleucel
21. Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001 - PubMed, accessed September 8, 2025, https://pubmed.ncbi.nlm.nih.gov/37890149/
22. Paper: Five-Year Survival of Patients (pts) from Transcend NHL 001 (TRANSCEND) Supports Curative Potential of Lisocabtagene Maraleucel (liso-cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL), accessed September 8, 2025, https://ash.confex.com/ash/2024/webprogram/Paper200204.html
23. Lisocabtagene Maraleucel Versus Standard of Care for Second ..., accessed September 8, 2025, https://ascopubs.org/doi/10.1200/JCO-25-00399
24. Lisocabtagene Maraleucel Superior to Standard of Care for Second-Line R/R LBCL: Updates From the TRANSFORM Study - Blood Cancers Today, accessed September 8, 2025, https://www.bloodcancerstoday.com/post/lisocabtagene-maraleucel-superior-to-standard-of-care-for-second-line-r-r-lbcl-updates-from-the-transform-study
25. Lisocabtagene Maraleucel Versus Standard of Care for Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up From the Randomized, Phase III TRANSFORM Study - PubMed, accessed September 8, 2025, https://pubmed.ncbi.nlm.nih.gov/40623279/
26. Lisocabtagene maraleucel for R/R LBCL in patients not intended for HSCT: final results of the phase 2 PILOT study | Blood Advances - ASH Publications, accessed September 8, 2025, https://ashpublications.org/bloodadvances/article/9/15/3694/537055/Lisocabtagene-maraleucel-for-R-R-LBCL-in-patients
27. Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study - PubMed, accessed September 8, 2025, https://pubmed.ncbi.nlm.nih.gov/35839786/
28. Lisocabtagene maraleucel as a second-line treatment for R/R LBCL: PROs from the PILOT study - Lymphoma Hub, accessed September 8, 2025, https://lymphomahub.com/medical-information/lisocabtagene-maraleucel-as-a-second-line-treatment-for-rr-lbcl-pros-from-the-pilot-study
29. Comparative efficacy of lisocabtagene maraleucel in the PILOT study versus second-line chemotherapy regimens in the real world - PubMed, accessed September 8, 2025, https://pubmed.ncbi.nlm.nih.gov/39479862/
30. Comparative efficacy of lisocabtagene maraleucel in the PILOT study versus second-line chemotherapy regimens in the real world | Haematologica, accessed September 8, 2025, https://haematologica.org/article/view/haematol.2024.285828
31. Lisocabtagene maraleucel for second-line relapsed or refractory large B-cell lymphoma: patient-reported outcomes from the PILOT study | Haematologica, accessed September 8, 2025, https://haematologica.org/article/view/11236
32. FDA Approval Summary: Lisocabtagene Maraleucel for Relapsed or Refractory Follicular Lymphoma - PMC, accessed September 8, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12369282/
33. Lisocabtagene maraleucel (intravenous route) - Side effects & uses - Mayo Clinic, accessed September 8, 2025, https://www.mayoclinic.org/drugs-supplements/lisocabtagene-maraleucel-intravenous-route/description/drg-20509577
34. Lisocabtagene maraleucel Recruiting Phase Trials for Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma | DrugBank Online, accessed September 8, 2025, https://go.drugbank.com/drugs/DB16582/clinical_trials?conditions=DBCOND0028332%2CDBCOND0023538&phase=&status=recruiting
35. Home | Breyanzi® (lisocabtagene maraleucel) CAR T Cell Therapy, accessed September 8, 2025, https://www.breyanzi.com/
36. Bristol Myers Squibb Announces Positive Topline Results from Phase 3 TRANSFORM Trial Evaluating Breyanzi (lisocabtagene maraleucel) Versus Chemotherapy Followed by Stem Cell Transplant in Second-line Relapsed or Refractory Large B-cell Lymphoma, accessed September 8, 2025, https://news.bms.com/news/details/2021/Bristol-Myers-Squibb-Announces-Positive-Topline-Results-from-Phase-3-TRANSFORM-Trial-Evaluating-Breyanzi-lisocabtagene-maraleucel-Versus-Chemotherapy-Followed-by-Stem-Cell-Transplant-in-Second-line-Relapsed-or-Refractory-Large-B-cell-Lymphoma/default.aspx
37. Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study | Blood - ASH Publications, accessed September 8, 2025, https://ashpublications.org/blood/article/141/14/1675/493847/Lisocabtagene-maraleucel-as-second-line-therapy
38. Lisocabtagene maraleucel for relapsed or refractory large B-cell lymphoma: feasibility, safety and efficacy in a real-world setting - Binaytara, accessed September 8, 2025, https://binaytara.org/journal/article/90694-lisocabtagene-maraleucel-for-relapsed-or-refractory-large-b-cell-lymphoma-feasibility-safety-and-efficacy-in-a-real-world-setting
39. BREYANZI® CAR T Cell Therapy | For Healthcare Providers, accessed September 8, 2025, https://www.breyanzihcp.com/
40. Lisocabtagene maraleucel for relapsed/refractory large B-cell lymphoma: a cell therapy consortium real-world analysis | Blood Advances | American Society of Hematology, accessed September 8, 2025, https://ashpublications.org/bloodadvances/article/9/5/1232/534450/Lisocabtagene-maraleucel-for-relapsed-refractory
41. Lisocabtagene maraleucel Completed Phase 2 Trials for Lymphatic Disorders / Diffuse Large B-Cell Lymphoma (DLBCL) / Immune System Diseases / Immunoproliferative Disorders / Non-Hodgkin's Lymphoma (NHL) Treatment - DrugBank, accessed September 8, 2025, https://go.drugbank.com/drugs/DB16582/clinical_trials?conditions=DBCOND0028221%2CDBCOND0029769%2CDBCOND0078368%2CDBCOND0042909%2CDBCOND0030854&phase=2&purpose=treatment&status=completed
42. Safety data of lisocabtagene maraleucel supports its use in an outpatient setting - BJH, accessed September 8, 2025, https://www.bjh.be/safety-data-of-lisocabtagene-maraleucel-supports-its-use-in-an-outpatient-setting/
43. Liso-Cel Has Favorable Safety Profile for Outpatients With Large B-Cell Lymphoma, accessed September 8, 2025, https://www.drugs.com/news/liso-cel-has-favorable-safety-profile-outpatients-large-b-cell-lymphoma-121719.html
44. Find a CAR T Cell Therapy Treatment Center | Breyanzi® (lisocabtagene maraleucel), accessed September 8, 2025, https://www.breyanzi.com/find-a-treatment-center
45. Starting Breyanzi® (lisocabtagene maraleucel), accessed September 8, 2025, https://www.breyanzi.com/starting-breyanzi
46. Large B-cell lymphoma (LBCL) Remission is Possible. Powered by ..., accessed September 8, 2025, https://www.breyanzi.com/assets/commercial/us/breyanzi/en/pdfs/Breyanzi_Patient_Brochure.pdf
47. Treatment Journey Resources | Breyanzi® (lisocabtagene maraleucel), accessed September 8, 2025, https://www.breyanzi.com/support/resources
48. Efficacy and Safety of CAR-T Cell Products Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel for the Treatment of Hematologic Malignancies: A Systematic Review and Meta-Analysis - Frontiers, accessed September 8, 2025, https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2021.698607/full
49. A real-world comparison of commercial-use axicabtagene ciloleucel ..., accessed September 8, 2025, https://ashpublications.org/bloodadvances/article/9/3/455/525995/A-real-world-comparison-of-commercial-use
50. Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel: Efficacy and Toxicity in a Real-World Setting | Blood, accessed September 8, 2025, https://ashpublications.org/blood/article/142/Supplement%201/2131/503343/Lisocabtagene-Maraleucel-Versus-Axicabtagene
51. A real-world comparison of commercial-use axicabtagene ciloleucel and lisocabtagene maraleucel in large B-cell lymphoma - ASTCT, accessed September 8, 2025, https://www.astct.org/Nucleus/Article/a-real-world-comparison-of-commercial-use-axicabtagene-ciloleucel-and-lisocabtagene-maraleucel-in-large-b-cell-lymphoma
52. Matching-adjusted indirect comparison (MAIC) of lisocabtagene maraleucel (liso-cel) versus axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) for treatment of third-line or later (3L+) R/R follicular lymphoma (FL) - ASCO Publications, accessed September 8, 2025, https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.e19049
53. Lisocabtagene maraleucel Recruiting Phase 2 Trials for Non-Hodgkin's lymphomas transformed recurrent Treatment | DrugBank Online, accessed September 8, 2025, https://go.drugbank.com/drugs/DB16582/clinical_trials?conditions=DBCOND0026827&phase=2&purpose=treatment&status=recruiting
54. Clinical Trials Using Lisocabtagene Maraleucel - NCI, accessed September 8, 2025, https://www.cancer.gov/research/participate/clinical-trials/intervention/lisocabtagene-maraleucel?pn=1
55. Study Details | NCT03744676 | A Safety Trial of Lisocabtagene ..., accessed September 8, 2025, https://clinicaltrials.gov/study/NCT03744676
56. NCT02631044 | Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001) | ClinicalTrials.gov, accessed September 8, 2025, https://www.clinicaltrials.gov/study/NCT02631044